CN116615430A - 杂环glp-1激动剂 - Google Patents

杂环glp-1激动剂 Download PDF

Info

Publication number
CN116615430A
CN116615430A CN202180073815.0A CN202180073815A CN116615430A CN 116615430 A CN116615430 A CN 116615430A CN 202180073815 A CN202180073815 A CN 202180073815A CN 116615430 A CN116615430 A CN 116615430A
Authority
CN
China
Prior art keywords
alkyl
compound
independently selected
compound according
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180073815.0A
Other languages
English (en)
Chinese (zh)
Inventor
邢唯强
张海珍
林熹晨
雷晖
A·詹宁斯
孟庆华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gashubrum Biology
Original Assignee
Gashubrum Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gashubrum Biology filed Critical Gashubrum Biology
Publication of CN116615430A publication Critical patent/CN116615430A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180073815.0A 2020-09-07 2021-09-06 杂环glp-1激动剂 Pending CN116615430A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020113758 2020-09-07
CNPCT/CN2020/113758 2020-09-07
PCT/CN2021/116684 WO2022048665A1 (en) 2020-09-07 2021-09-06 Heterocyclic glp-1 agonists

Publications (1)

Publication Number Publication Date
CN116615430A true CN116615430A (zh) 2023-08-18

Family

ID=80491636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180073815.0A Pending CN116615430A (zh) 2020-09-07 2021-09-06 杂环glp-1激动剂

Country Status (5)

Country Link
US (1) US20230322771A1 (https=)
EP (1) EP4211133A4 (https=)
JP (1) JP7821785B2 (https=)
CN (1) CN116615430A (https=)
WO (1) WO2022048665A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119176808A (zh) * 2024-11-25 2024-12-24 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用
WO2025119206A1 (en) * 2023-12-05 2025-06-12 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206429A (zh) 2020-04-29 2022-02-16 美商迦舒布魯姆生物有限公司 雜環ｇｌｐ—１促效劑
JP2023537501A (ja) 2020-08-06 2023-09-01 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
CN116368140A (zh) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023029380A1 (zh) 2021-08-30 2023-03-09 杭州德睿智药科技有限公司 作为glp1r激动剂的新型芳醚取代杂环类化合物
PT4408840T (pt) 2021-09-27 2025-10-07 Terns Pharmaceuticals Inc Ácidos benzimidazolocarboxílicos como agonistas de glp-1r
CN118401519A (zh) 2021-10-25 2024-07-26 拓臻制药公司 作为glp-1r激动剂的化合物
CN119095843A (zh) 2022-02-23 2024-12-06 拓臻制药公司 作为glp-1r激动剂的化合物
US20250206757A1 (en) * 2022-03-21 2025-06-26 Gasherbrum Bio, Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
EP4522131A1 (en) * 2022-05-11 2025-03-19 Eli Lilly and Company Glp1 tablet compositions
EP4652167A1 (en) * 2023-01-17 2025-11-26 Fochon Biosciences, Ltd. Glp-1r agonists and uses thereof
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4568664B1 (en) 2023-04-07 2026-04-01 Terns Pharmaceuticals, Inc. Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity
WO2025002250A1 (zh) * 2023-06-29 2025-01-02 韦恩生物科技有限公司 一种glp-1受体激动剂及其制备方法和用途
IL325536A (en) * 2023-06-30 2026-02-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd A compound containing a multi-fused ring structure
TW202508571A (zh) * 2023-07-28 2025-03-01 大陸商上海翰森生物醫藥科技有限公司 一種苯并含氮雜環類衍生物調節劑、其製備方法和應用
WO2025026436A1 (zh) * 2023-08-02 2025-02-06 韦恩生物科技有限公司 一种含氮并环化合物及其制备方法和用途
WO2025045208A1 (en) * 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
CN120981457A (zh) * 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
CN121941685A (zh) 2023-11-10 2026-04-28 重庆药友制药有限责任公司 一种glp-1r激动剂化合物及其应用
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法
WO2025209515A1 (zh) * 2024-04-03 2025-10-09 广州市联瑞制药有限公司 一种glp-1受体激动剂及其制备方法和应用
WO2025264023A1 (en) * 2024-06-19 2025-12-26 Chong Kun Dang Pharmaceutical Corp. Glp-1 receptor agonist, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927214B1 (en) * 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
CN109790161A (zh) * 2016-09-26 2019-05-21 中外制药株式会社 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
JP2019099571A (ja) * 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927214B1 (en) * 1999-01-15 2005-08-09 Novo Nordisk A/S Non-peptide GLP-1 agonists
CN109790161A (zh) * 2016-09-26 2019-05-21 中外制药株式会社 具有glp-1受体激动剂作用的吡唑并吡啶衍生物
JP2019099571A (ja) * 2017-11-29 2019-06-24 中外製薬株式会社 Ｇｌｐ−１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025119206A1 (en) * 2023-12-05 2025-06-12 Fortvita Biologics Inc. Glp-1 receptor targeting compounds and uses thereof
WO2026031819A1 (en) * 2024-08-06 2026-02-12 Insilico Medicine Ip Limited Novel compounds as glp-1r agonists and uses thereof
CN119176808A (zh) * 2024-11-25 2024-12-24 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用
CN119176808B (zh) * 2024-11-25 2025-12-26 山东法恩新材料科技有限公司 一种glp-1激动剂及其制备方法和应用

Also Published As

Publication number Publication date
EP4211133A4 (en) 2024-11-27
JP2023540558A (ja) 2023-09-25
WO2022048665A1 (en) 2022-03-10
EP4211133A1 (en) 2023-07-19
US20230322771A1 (en) 2023-10-12
JP7821785B2 (ja) 2026-02-27

Similar Documents

Publication Publication Date Title
JP7821785B2 (ja) ヘテロ環ｇｌｐ－１アゴニスト
US12595264B2 (en) Heterocyclic GLP-1 agonists
US11897851B2 (en) Heterocyclic GLP-1 agonists
US20240366639A1 (en) Heterocyclic glp-1 agonists
WO2022078380A1 (en) Heterocyclic glp-1 agonists
WO2022042691A1 (en) Heterocyclic glp-1 agonists
EP4490155A1 (en) Heterocyclic glp-1 agonists
EP4476216A1 (en) Heterocyclic glp-1 agonists
WO2023151575A1 (en) Heterocyclic glp-1 agonists
EP4508047A1 (en) Heterocyclic glp-1 agonists
WO2025045208A1 (en) Heteroaryl-heterocycloalkyl-based glp-1 agonists
TW202506102A (zh) 雜環的glp-1促效劑
HK40098769A (zh) 杂环glp-1激动剂
KR20260064683A (ko) 헤테로시클릭 glp-1 효능제
HK40119249A (zh) 杂环glp-1激动剂
HK40122544A (zh) 杂环glp-1激动剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40098769

Country of ref document: HK